Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine

摘要: Background: Metabolic syndrome (obesity, glucose intolerance, insulin resistance and dyslipidaemia) is a well-known adverse effect of most antipsychotics. It particularly common in patients treated with olanzapine clozapine. Currently, the mechanisms underlying its development are not completely understood. Case report: We present case improved body composition (reduced amount total fat visceral adipose tissue), anthropometric measurements (body weight, waist, abdominal hip circumferences) lipid profile 31-year-old man schizophrenia following discontinuation During combined treatment clozapine, flupentixol ziprasidone, routine laboratory test revealed severe dyslipidaemia (triglycerides > 1800 mg/dL; 20.3 mmol/L), despite previous lipid-lowering therapy. This abnormality recovered after clozapine has been discontinued. Conclusions: Clozapine may cause severe, but reversible metabolic abnormalities, including obesity hy...